Orion Diu (olmesartan medoxomil + hydroclorothiazide): Uses, Dosage & Side Effects

What it's for (Indications)

Olmesartan medoxomil + hydrochlorothiazide is indicated for the treatment of essential hypertension in adult patients.
This fixed-dose combination medication is specifically formulated for individuals whose blood pressure is not adequately controlled with monotherapy of either olmesartan medoxomil or hydrochlorothiazide alone.
It is not recommended for initial therapy of hypertension.
Instead, it serves as an effective step-up therapy for patients requiring additional blood pressure reduction after failing to achieve target blood pressure goals on a single antihypertensive agent.
By synergistically combining an angiotensin II receptor blocker (olmesartan) with a thiazide diuretic (hydrochlorothiazide), this medication provides a potent and additive antihypertensive effect, leading to a greater reduction in systemic blood pressure compared to either component administered separately.
Effective and sustained control of hypertension is paramount for mitigating the long-term risks of serious cardiovascular events, including but not limited to stroke, myocardial infarction, and congestive heart failure, thereby improving patient outcomes and reducing cardiovascular morbidity and mortality.

Dosage Information

Type	Guideline
Standard	For patients whose blood pressure is not adequately controlled with olmesartan monotherapy, the recommended starting dose is 40/12.5 mg once daily. For patients not adequately controlled with hydrochlorothiazide monotherapy or who experience dose-limiting adverse reactions with hydrochlorothiazide, the recommended starting dose is 20/12.5 mg once daily. The dose can be titrated up to 40/25 mg once daily if necessary. Patients titrated to the individual components (olmesartan and hydrochlorothiazide) may receive the corresponding fixed-dose combination.

Type

Guideline

Standard

For patients whose blood pressure is not adequately controlled with olmesartan monotherapy, the recommended starting dose is 40/12.5 mg once daily. For patients not adequately controlled with hydrochlorothiazide monotherapy or who experience dose-limiting adverse reactions with hydrochlorothiazide, the recommended starting dose is 20/12.5 mg once daily. The dose can be titrated up to 40/25 mg once daily if necessary. Patients titrated to the individual components (olmesartan and hydrochlorothiazide) may receive the corresponding fixed-dose combination.

Safety & Warnings

Common Side Effects

Commonly reported adverse reactions include dizziness, headache, nausea, hyperuricemia, and upper respiratory infection.
Other possible side effects include edema, fatigue, hypotension (especially in volume- or salt-depleted patients), impaired renal function, hypersensitivity reactions, electrolyte and metabolic imbalances, acute myopia and secondary angle-closure glaucoma, systemic lupus erythematosus, and sprue-like enteropathy.

Serious Warnings

Black Box Warning: WARNING: FETAL TOXICITY. When pregnancy is detected, discontinue olmesartan medoxomil and hydrochlorothiazide tablets as soon as possible. Drugs that act directly on the renin-angiotensin system (RAS) can cause injury and death to the developing fetus.
This medicine is contraindicated in pregnant females due to the risk of fetal injury and death.
If pregnancy is detected, discontinue treatment as soon as possible.
It is also contraindicated in lactating mothers; consult your doctor if there is no other alternative medicine.
Avoid consuming alcohol when taking this medicine.
Use with caution in individuals suffering from intravascular volume depletion, aortic or mitral valve stenosis (narrowing of heart’s mitral and aortic valve), obstructive hypertrophic cardiomyopathy, and primary aldosteronism.
Patients with liver impairment should use this medicine with caution.
Individuals with excessively low blood pressure, particularly those with ischemic heart disease or ischemic cerebrovascular disease, should be monitored closely as this may result in myocardial infarction (MI) or stroke.
Potential adverse reactions requiring caution include hypotension in volume- or salt-depleted patients, impaired renal function, hypersensitivity reactions, electrolyte and metabolic imbalances, acute myopia and secondary angle-closure glaucoma, systemic lupus erythematosus, and sprue-like enteropathy.

How it Works (Mechanism of Action)

Olmesartan medoxomil acts as an angiotensin II receptor blocker (ARB) by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle. Angiotensin II, formed from angiotensin I by ACE, is the principal pressor agent of the renin-angiotensin system, mediating vasoconstriction, aldosterone synthesis and release, cardiac stimulation, and renal reabsorption of sodium. Olmesartan's action is independent of angiotensin II synthesis pathways, and its blockade of the AT1 receptor inhibits these effects and the negative regulatory feedback of angiotensin II on renin secretion.